Pfizer Oncology Pipeline Takes Hit With Dacomitinib Lung Failure

Expectations for the asset hadn’t been high, but failure of two Phase III lung cancer studies of the irreversible pan-HER inhibitor dacomitinib may remove a potential competitor for Boehringer Ingelheim’s recently approved irreversible EGFR inhibitor Gilotrif.